1
|
Gomez-Salinero JM, Itkin T, Houghton S, Badwe C, Lin Y, Kalna V, Dufton N, Peghaire CR, Yokoyama M, Wingo M, Lu TM, Li G, Xiang JZ, Hsu YMS, Redmond D, Schreiner R, Birdsey GM, Randi AM, Rafii S. Cooperative ETS Transcription Factors Enforce Adult Endothelial Cell Fate and Cardiovascular Homeostasis. Nat Cardiovasc Res 2022; 1:882-899. [PMID: 36713285 PMCID: PMC7614113 DOI: 10.1038/s44161-022-00128-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 08/04/2022] [Indexed: 01/31/2023]
Abstract
Current dogma dictates that during adulthood, endothelial cells (ECs) are locked in an immutable stable homeostatic state. By contrast, herein we show that maintenance of EC fate and function are linked and active processes, which depend on the constitutive cooperativity of only two ETS-transcription factors (TFs) ERG and Fli1. While deletion of either Fli1 or ERG manifest subtle vascular dysfunction, their combined genetic deletion in adult EC results in acute vasculopathy and multiorgan failure, due to loss of EC fate and integrity, hyperinflammation, and spontaneous thrombosis, leading to death. ERG and Fli1 co-deficiency cause rapid transcriptional silencing of pan- and organotypic vascular core genes, with dysregulation of inflammation and coagulation pathways. Vascular hyperinflammation leads to impaired hematopoiesis with myeloid skewing. Accordingly, enforced ERG and FLI1 expression in adult human mesenchymal stromal cells activates vascular programs and functionality enabling engraftment of perfusable vascular network. GWAS-analysis identified vascular diseases are associated with FLI1/Erg mutations. Constitutive expression of ERG and Fli1 uphold EC fate, physiological function, and resilience in adult vasculature; while their functional loss can contribute to systemic human diseases.
Collapse
Affiliation(s)
- Jesus M Gomez-Salinero
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Tomer Itkin
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Sean Houghton
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Chaitanya Badwe
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Yang Lin
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Viktoria Kalna
- National Heart and Lung Institute, Imperial College London, London, UK
- Human Genetics and Computational Biology GSK, UK (current address)
| | - Neil Dufton
- National Heart and Lung Institute, Imperial College London, London, UK
- Queen Mary University of London, Centre for Microvascular Research, William Harvey Research Centre, UK (current address)
| | - Claire R Peghaire
- National Heart and Lung Institute, Imperial College London, London, UK
- University of Bordeaux, Inserm UMR1034, Biology of Cardiovascular Diseases, Pessac, France (current address)
| | - Masataka Yokoyama
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Matthew Wingo
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Tyler M. Lu
- Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medicine, New York, NY 10065, USA
| | - Ge Li
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | | | - Yen-Michael Sheng Hsu
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
- Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA (current address)
- Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA (current address)
| | - David Redmond
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Ryan Schreiner
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| | - Graeme M Birdsey
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Anna M Randi
- National Heart and Lung Institute, Imperial College London, London, UK
| | - Shahin Rafii
- Division of Regenerative Medicine, Hartman Institute for Therapeutic Organ Regeneration, Ansary Stem Cell Institute, Department of Medicine, Weill Cornell Medicine, NY, USA
| |
Collapse
|
2
|
Guleria I, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu YMS, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok-Pizzini D, Reich-Slotky R, Spitzer T. How do I: Evaluate the safety and legitimacy of unproven cellular therapies? Transfusion 2022; 62:518-532. [PMID: 35143051 DOI: 10.1111/trf.16814] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 01/16/2022] [Accepted: 01/16/2022] [Indexed: 02/05/2023]
Abstract
BACKGROUND Unproven cellular therapies are being offered to patients for a variety of conditions and diseases for which other treatments have failed. The use of untested cellular therapies is a worldwide problem. Practitioners (e.g., physicians, scientists, QA/QI facility managers, and policy advocates) are perhaps unaware of the risks involved with such therapies. Therefore, a critical need exists to bring attention to the potential limitations and adverse effects of these therapies to inform and limit misinformation. STUDY DESIGN AND METHODS We describe the extent of the unproven cellular therapy problem through a search of scientific literature and social media coverage. We also describe the regulatory framework that can be used by the practitioner to review and evaluate both proven and unproven cellular therapies. RESULTS We report on the current state of unproven cellular therapies across the globe. A workflow to facilitate an understanding of the regulatory processes involved in the approval of cellular therapies is provided as well as a list of warnings required by regulatory agencies on various products. It is hoped that this article will serve as a tool kit to educate the practitioner on navigating the field of unproven cellular therapy products. DISCUSSION Increasing awareness of the issues associated with unproven therapies through education is important to help in reducing misinformation and risks to patients.
Collapse
Affiliation(s)
- Indira Guleria
- Renal Transplant Program, Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
- Harvard Medical School, Boston, Massachusetts, USA
| | - Maria de Los Angeles Muñiz
- Transfusion Medicine and Cellular Therapy Division, Department of Pathology, Weill Cornell Medicine, New York, New York, USA
| | - Matthew Wilgo
- New England Cord Blood Bank, Inc., New England Cryogenic Center. Inc., Marlborough, Massachusetts, USA
| | - Asawari Bapat
- Department of Quality and Regulatory Affairs, Infohealth FZE and Questar Enterprises, Dubai, UAE
| | - Wanxing Cui
- Cell Therapy Manufacturing Facility, Department of Pathology and Laboratory Medicine, MedStar Georgetown University Hospital, Gerorgetown, Washington, District of Columbia, USA
| | - Yen-Michael Sheng Hsu
- Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA
| | - Madhan Jeyaraman
- Department of Orthopaedics, Faculty of Medicine, Sri Lalithambigai Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai, India
- Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India
| | - Sathish Muthu
- Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India
- Department of Orthopaedics, Government Medical College and Hospital, Dindigul, India
| | - Federico Rodriguez
- Collections and Processing Facility, Bone Marrow Transplant Program, UF Health Shands Cancer Hospital, Gainsville, Florida, USA
| | - Andrew Fesnak
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Christina Celluzzi
- Department of Biotherapies, Association for the Advancement of Blood and Biotherapies, Bethesda, Maryland, USA
| | - Deborah Sesok-Pizzini
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Ronit Reich-Slotky
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Thomas Spitzer
- Harvard Medical School, Boston, Massachusetts, USA
- Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Reich-Slotky R, Al-Mulla N, Hafez R, Segovia-Gomez J, Goel R, Mayer S, Phillips A, Shore TB, Jing-Mei H, Hsu YMS, Vasovic LV, Cushing MM, Gergis U. Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 2020; 61:2894-2899. [PMID: 32662694 DOI: 10.1080/10428194.2020.1789622] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
PGF implies persistent cytopenia in the presence of predominant donor chimerism. We examined contributors to PGF in 104 HCT recipients who survived ≥100 days without relapse or major complications. Surrogate parameters for PGF were: Hg <10 g/dl, RBC transfusion dependence, platelet count <20 × 109/L or ANC < 0.5 × 109/L. All patients received T cell depletion with alemtuzumab or ATG. The 2-year OS and PFS probabilities were 66%, 95%CI (56 - 75%) and 51%, 95%CI (41-60%) respectively. Fifty-four patients (52%) met one or more PGF criteria. There was significant association between major ABO incompatibility and platelet <20 × 109/L (OR = 4.7, 95%CI 1.05-21.26, p = .043), acute GVHD and Hg <10 g/dl (OR 3.7, 95%CI 1.4-9.6, p = .005) and CMV viremia and ANC < 0.5 × 109/L (OR 3.0, 95% CI 1.0, 8.7, p = .043). NRM was significantly higher in the PGF group compared to patients with adequate graft function (45.5% vs 16.7%, p = .014).
Collapse
Affiliation(s)
| | | | - Rania Hafez
- Clinical Hematology Unit, Internal Medicine Department, Assiut University, Egypt
| | | | - Ruchika Goel
- Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.,Simmons Cancer Institute at SIU School of Medicine, Springfield, IL, USA
| | - Sebastian Mayer
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Adrienne Phillips
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Tsiporah B Shore
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Hsu Jing-Mei
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Yen-Michael Sheng Hsu
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Ljiljana V Vasovic
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Melissa M Cushing
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| | - Usama Gergis
- Pathology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA
| |
Collapse
|
4
|
Droll SH, Sheng Hsu YM, Drake SK, Kim A, Wang W, Calvo KR, Cao Z, Hu TY, Zhao Z. Differential processing of high-molecular-weight kininogen during normal pregnancy. Rapid Commun Mass Spectrom 2020; 34 Suppl 1:e8552. [PMID: 31412146 PMCID: PMC7018535 DOI: 10.1002/rcm.8552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Revised: 07/18/2019] [Accepted: 08/07/2019] [Indexed: 06/10/2023]
Abstract
RATIONALE Studies identified kininogen as a potential biomarker of preeclampsia, a major cause of adverse maternal outcomes. High-molecular-weight kininogen (HK) and its activated form participate in numerous pathways associated with establishing and maintaining pregnancy. However, dynamic changes in HK and naturally occurring HK-derived peptides during the natural course of pregnancy are largely unknown. METHODS Longitudinal serum samples during the course of normal pregnancy (trimesters T1, T2, T3) from 60 pregnant women were analyzed by western blot with an anti-HK antibody. Circulating peptides in longitudinal serum specimens derived from 50 participants were enriched using nanoporous silica thin films. Peptides were identified by liquid chromatography/tandem mass spectrometry (LC/MS/MS) and database searching. Relative quantification was performed using MaxQuant and in-house scripts. Normality was evaluated by either ANOVA or Friedman tests with p < 0.05 for statistical significance. RESULTS Western blotting revealed that HK significantly decreased during normal pregnancy (T1 vs T2, p < 0.05; T1 vs T3, p < 0.0001). A 100 kDa intermediate increased during pregnancy (T1 vs T2, p < 0.005; T1 vs T3, p < 0.01). Moreover, the heavy chain (T1 vs T2, p < 0.0001; T1 vs T3, p < 0.0001; T2 vs T3, p < 0.01) and light chain (T1 vs T2, p < 0.0001; T1 vs T3, p < 0.0001; T2 vs T3, p < 0.05) significantly increased during pregnancy. LC/MS/MS analysis identified 180 kininogen-1 peptides, of which 167 mapped to domain 5 (D5). Seventy-three peptides with ten or more complete data sets were included for further analysis. Seventy peptides mapped to D5, and 3, 24, and 43 peptides showed significant decrease, no trend, and significant increase, respectively, during pregnancy. CONCLUSIONS This study demonstrates dynamic changes in HK and naturally occurring HK-derived peptides during pregnancy. Our study sheds light on the gestational changes of HK and its peptides for further validation of them as potential biomarkers for pregnancy-related complications.
Collapse
Affiliation(s)
- Stephenie H. Droll
- Chemistry Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, 20892 MD, USA
- IBiS - Department of Molecular Biosciences, Northwestern University, Evanston, Illinois 60208-3500
| | - Yen-Michael Sheng Hsu
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065
| | - Steven K. Drake
- Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| | - Ashley Kim
- Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853
| | - Weixin Wang
- Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, 20892 MD, USA
| | - Katherine R. Calvo
- Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, 20892 MD, USA
| | - Zheng Cao
- Department of Laboratory Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
| | - Tony Y Hu
- Virginia G. Piper Biodesign Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University; School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ 85281
| | - Zhen Zhao
- Chemistry Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, 20892 MD, USA
- Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065
| |
Collapse
|